# multiple myeloma FDA approvals and PDUFA dates

Canonical: https://sec-api.dev/indications/multiple-myeloma

> 46 upcoming FDA catalysts in multiple myeloma: anitocabtagene autoleucel (GILD) on December 2026 (primary completion); anitocabtagene autoleucel (GILD) on Dec 2026 to Mar 2027 (topline data readout); DARZALEX (daratumumab, JNJ) on Feb to May 2027 (topline data readout); DARZALEX (daratumumab, JNJ) on February 2027 (primary completion); and 42 more.

Data as of November 16, 2026 (snapshot 20261116T222116Z). Every date quotes the SEC filing or FDA page it came from. Date precision: month only, exact day, quarter only.

**Free:** every drug page and the next 30 days of the FDA calendar, no account. Calendar API, alerts when a date moves, and full history: https://sec-api.dev/pricing . Free API key: https://sec-api.dev/sign-up?ref=ai-claudebot

## Catalysts

| Date | Event | Ticker | Indication | Status | Source sentence |
| --- | --- | --- | --- | --- | --- |
| Sep 2022 | [APHEXDA® (motixafortide) FDA approval](https://sec-api.dev/pdufa/motixafortide) | BLRX | multiple myeloma | completed, approved | "In September 2022, we submitted an NDA to the FDA for motixafortide in stem cell mobilization for autologous bone marrow transplantation for multiple myeloma patients and as noted above in September 2023, the FDA approved motixafortide in combination with G-CSF to mobilize hematopoietic stem cells to the peripheral blood for collection and subsequent autologous transplantation in patients with multiple myeloma." ([SEC Form 10-K](https://www.sec.gov/Archives/edgar/data/1498403/000117891325001123/zk2532907.htm)) |
| Sep 2022 | [APHEXDA® (motixafortide) NDA/BLA submission](https://sec-api.dev/pdufa/motixafortide) | BLRX | multiple myeloma | completed | "In September 2022, we submitted an NDA to the FDA for motixafortide in stem cell mobilization for autologous bone marrow transplantation for multiple myeloma patients and as noted above in September 2023, the FDA approved motixafortide in combination with G-CSF to mobilize hematopoietic stem cells to the peripheral blood for collection and subsequent autologous transplantation in patients with multiple myeloma." ([SEC Form 10-K](https://www.sec.gov/Archives/edgar/data/1498403/000117891325001123/zk2532907.htm)) |
| September 8, 2023 | [APHEXDA® (motixafortide) FDA approval](https://sec-api.dev/pdufa/motixafortide) | BLRX | multiple myeloma | completed, approved | "In September 2023, the U.S. Food and Drug Administration ("FDA") approved motixafortide in stem cell mobilization for autologous transplantation for multiple myeloma patients, and the Company began to independently commercialize motixafortide in the U.S." ([Press release filed with the SEC (EX-99)](https://www.sec.gov/Archives/edgar/data/1498403/000117891326004331/exhibit_2.htm)) |
| February 11, 2025 | [Adaptive Biotechnologies Corp FDA advisory committee meeting](https://sec-api.dev/companies/adpt/catalysts) | ADPT | multiple myeloma | completed, positive | "The FDA's Oncologic Drug Advisory Committee (ODAC) voted unanimously in favor of the use of MRD as a primary endpoint to support the accelerated approval of new therapies for patients with multiple myeloma." ([Press release filed with the SEC (EX-99)](https://www.sec.gov/Archives/edgar/data/1478320/000095017025017915/adpt-ex99_1.htm)) |
| May 21, 2025 | [PHE885 primary completion](https://sec-api.dev/pdufa/phe885) | NVS | Multiple Myeloma | withdrawn | "NCT05172596 (PHE885 CAR-T Therapy in Adult Participants With Relapsed and Refractory Multiple Myeloma): Overall Status TERMINATED; Phase PHASE2; Primary Completion 2025-05-21 (ACTUAL); Lead Sponsor Novartis Pharmaceuticals." ([ClinicalTrials.gov](https://clinicaltrials.gov/study/NCT05172596)) |
| August 1, 2025 | [DARZALEX (daratumumab) primary completion](https://sec-api.dev/pdufa/daratumumab) | JNJ | Multiple Myeloma | completed | "NCT05083169 (A Study of Teclistamab in Combination With Daratumumab Subcutaneously (SC) (Tec-Dara) Versus Daratumumab SC, Pomalidomide, and Dexamethasone (DPd) or Daratumumab SC, Bortezomib, and Dexamethasone (DVd) in Participants With Relapsed or Refractory Multiple Myeloma): Overall Status ACTIVE_NOT_RECRUITING; Phase PHASE3; Primary Completion 2025-08-01 (ACTUAL); Lead Sponsor Janssen Research & Development, LLC." ([ClinicalTrials.gov](https://clinicaltrials.gov/study/NCT05083169)) |
| August 11, 2025 | [ABECMA (idecabtagene vicleucel) primary completion](https://sec-api.dev/pdufa/idecabtagene-vicleucel) | BMY | Multiple Myeloma | completed | "NCT06045806 (A Study to Compare the Efficacy and Safety of Idecabtagene Vicleucel With Lenalidomide Maintenance Therapy Versus Lenalidomide Maintenance Therapy Alone in Adult Participants With Newly Diagnosed Multiple Myeloma Who Have Suboptimal Response After Autologous Stem Cell Transplantation): Overall Status ACTIVE_NOT_RECRUITING; Phase PHASE3; Primary Completion 2025-08-11 (ACTUAL); Lead Sponsor Celgene." ([ClinicalTrials.gov](https://clinicaltrials.gov/study/NCT06045806)) |
| October 13, 2025 | [TECVAYLI (teclistamab) primary completion](https://sec-api.dev/pdufa/teclistamab) | JNJ | Multiple Myeloma | completed | "NCT05572515 (A Study Comparing Teclistamab Monotherapy Versus Pomalidomide, Bortezomib, Dexamethasone (PVd) or Carfilzomib, Dexamethasone (Kd) in Participants With Relapsed or Refractory Multiple Myeloma): Overall Status ACTIVE_NOT_RECRUITING; Phase PHASE3; Primary Completion 2025-10-13 (ACTUAL); Lead Sponsor Janssen Research & Development, LLC." ([ClinicalTrials.gov](https://clinicaltrials.gov/study/NCT05572515)) |
| January 15, 2026 | [BB2121 primary completion](https://sec-api.dev/pdufa/bb2121) | BMY | Multiple Myeloma | completed | "NCT03601078 (An Efficacy and Safety Study of bb2121 in Subjects With Relapsed and Refractory Multiple Myeloma and in Subjects With High-Risk Multiple Myeloma): Overall Status COMPLETED; Phase PHASE2; Primary Completion 2026-01-15 (ACTUAL); Lead Sponsor Celgene." ([ClinicalTrials.gov](https://clinicaltrials.gov/study/NCT03601078)) |
| February 23, 2026 | [Empliciti (elotuzumab) primary completion](https://sec-api.dev/pdufa/elotuzumab) | BMY | Multiple Myeloma | completed | "NCT02719613 (Continuing Treatment for Participants Who Have Participated in a Prior Protocol Investigating Elotuzumab): Overall Status COMPLETED; Phase PHASE2; Primary Completion 2026-02-23 (ACTUAL); Lead Sponsor Bristol-Myers Squibb." ([ClinicalTrials.gov](https://clinicaltrials.gov/study/NCT02719613)) |
| February 26, 2026 | [Elrexfio (elranatamab) primary completion](https://sec-api.dev/pdufa/elranatamab) | PFE | Multiple Myeloma | completed | "NCT05020236 (A Study to Learn About the Study Medicine Elranatamab Alone and With Daratumumab in People With Multiple Myeloma Who Have Received Other Treatments): Overall Status RECRUITING; Phase PHASE3; Primary Completion 2026-02-26 (ACTUAL); Lead Sponsor Pfizer." ([ClinicalTrials.gov](https://clinicaltrials.gov/study/NCT05020236)) |
| April 1, 2026 | [Talquetamab primary completion](https://sec-api.dev/pdufa/talquetamab) | JNJ | Multiple Myeloma | completed | "NCT06208150 (A Study Comparing Talquetamab Plus Pomalidomide, Talquetamab Plus Teclistamab, and Elotuzumab, Pomalidomide, and Dexamethasone or Pomalidomide, Bortezomib, and Dexamethasone in Participants With Relapsed or Refractory Myeloma Who Have Received an Anti-CD38 Antibody and Lenalidomide): Overall Status ACTIVE_NOT_RECRUITING; Phase PHASE3; Primary Completion 2026-04-01 (ACTUAL); Lead Sponsor Janssen Research & Development, LLC." ([ClinicalTrials.gov](https://clinicaltrials.gov/study/NCT06208150)) |
| April 13, 2026 | [Pomalyst (pomalidomide) primary completion](https://sec-api.dev/pdufa/pomalidomide) | BMY | Multiple Myeloma | completed | "NCT03651128 (Efficacy and Safety Study of bb2121 Versus Standard Regimens in Subjects With Relapsed and Refractory Multiple Myeloma (RRMM)): Overall Status COMPLETED; Phase PHASE3; Primary Completion 2026-04-13 (ACTUAL); Lead Sponsor Celgene." ([ClinicalTrials.gov](https://clinicaltrials.gov/study/NCT03651128)) |
| July 31, 2026 | [Arlocabtagene autoleucel primary completion](https://sec-api.dev/pdufa/arlocabtagene-autoleucel) | BMY | Multiple Myeloma | completed | "NCT06297226 (Study of Arlocabtagene Autoleucel (BMS-986393) a GPRC5D-directed CAR T Cell Therapy in Adult Participants With Relapsed or Refractory Multiple Myeloma): Overall Status RECRUITING; Phase PHASE2; Primary Completion 2026-07-31 (ACTUAL); Lead Sponsor Juno Therapeutics, Inc., a Bristol-Myers Squibb Company." ([ClinicalTrials.gov](https://clinicaltrials.gov/study/NCT06297226)) |
| August 2026 | [Venclexta (venetoclax) primary completion](https://sec-api.dev/pdufa/venetoclax) | ABBV | Multiple Myeloma | delayed | "NCT03539744 (A Study Designed to Evaluate the Safety and Efficacy of Venetoclax Plus Dexamethasone (VenDex) Compared With Pomalidomide Plus Dexamethasone (PomDex) in Participants With t(11;14)-Positive Relapsed or Refractory Multiple Myeloma.): Overall Status ACTIVE_NOT_RECRUITING; Phase PHASE3; Primary Completion 2026-08 (ESTIMATED); Lead Sponsor AbbVie." ([ClinicalTrials.gov](https://clinicaltrials.gov/study/NCT03539744)) |
| Aug to Nov 2026 | [Venclexta (venetoclax) topline data readout](https://sec-api.dev/pdufa/venetoclax) | ABBV | Multiple Myeloma | scheduled | "NCT03539744 (A Study Designed to Evaluate the Safety and Efficacy of Venetoclax Plus Dexamethasone (VenDex) Compared With Pomalidomide Plus Dexamethasone (PomDex) in Participants With t(11;14)-Positive Relapsed or Refractory Multiple Myeloma.): Overall Status ACTIVE_NOT_RECRUITING; Phase PHASE3; Primary Completion 2026-08 (ESTIMATED); Lead Sponsor AbbVie." ([ClinicalTrials.gov](https://clinicaltrials.gov/study/NCT03539744)) |
| August 26, 2026 | [Elrexfio (elranatamab) primary completion](https://sec-api.dev/pdufa/elranatamab) | PFE | Multiple Myeloma | completed | "NCT06152575 (MagnetisMM-32: A Study to Learn About the Study Medicine Called Elranatamab in People With Multiple Myeloma (MM) That Has Come Back After Taking Other Treatments (Including Prior Treatment With an Anti-CD38 Antibody and Lenalidomide)): Overall Status RECRUITING; Phase PHASE3; Primary Completion 2026-08-26 (ACTUAL); Lead Sponsor Pfizer." ([ClinicalTrials.gov](https://clinicaltrials.gov/study/NCT06152575)) |
| Aug to Nov 2026 | [Elrexfio (elranatamab) topline data readout](https://sec-api.dev/pdufa/elranatamab) | PFE | Multiple Myeloma | scheduled | "NCT06152575 (MagnetisMM-32: A Study to Learn About the Study Medicine Called Elranatamab in People With Multiple Myeloma (MM) That Has Come Back After Taking Other Treatments (Including Prior Treatment With an Anti-CD38 Antibody and Lenalidomide)): Overall Status RECRUITING; Phase PHASE3; Primary Completion 2026-08-26 (ACTUAL); Lead Sponsor Pfizer." ([ClinicalTrials.gov](https://clinicaltrials.gov/study/NCT06152575)) |
| December 2026 | [Anitocabtagene autoleucel primary completion](https://sec-api.dev/pdufa/anitocabtagene-autoleucel) | GILD | Multiple Myeloma | scheduled | "NCT05396885 (Study of Anitocabtagene-autoleucel in Relapsed or Refractory Multiple Myeloma (iMMagine-1)): Overall Status ACTIVE_NOT_RECRUITING; Phase PHASE2; Primary Completion 2026-12 (ESTIMATED); Lead Sponsor Kite, A Gilead Company." ([ClinicalTrials.gov](https://clinicaltrials.gov/study/NCT05396885)) |
| Dec 2026 to Mar 2027 | [Anitocabtagene autoleucel topline data readout](https://sec-api.dev/pdufa/anitocabtagene-autoleucel) | GILD | Multiple Myeloma | scheduled | "NCT05396885 (Study of Anitocabtagene-autoleucel in Relapsed or Refractory Multiple Myeloma (iMMagine-1)): Overall Status ACTIVE_NOT_RECRUITING; Phase PHASE2; Primary Completion 2026-12 (ESTIMATED); Lead Sponsor Kite, A Gilead Company." ([ClinicalTrials.gov](https://clinicaltrials.gov/study/NCT05396885)) |
| Feb to May 2027 | [DARZALEX (daratumumab) topline data readout](https://sec-api.dev/pdufa/daratumumab) | JNJ | Multiple Myeloma | scheduled | "NCT04133636 (A Study of JNJ-68284528, a Chimeric Antigen Receptor T Cell (CAR-T) Therapy Directed Against B-cell Maturation Antigen (BCMA) in Participants With Multiple Myeloma): Overall Status ACTIVE_NOT_RECRUITING; Phase PHASE2; Primary Completion 2027-02-26 (ESTIMATED); Lead Sponsor Janssen Research & Development, LLC." ([ClinicalTrials.gov](https://clinicaltrials.gov/study/NCT04133636)) |
| February 2027 | [DARZALEX (daratumumab) primary completion](https://sec-api.dev/pdufa/daratumumab) | JNJ | Multiple Myeloma | scheduled | "NCT04133636 (A Study of JNJ-68284528, a Chimeric Antigen Receptor T Cell (CAR-T) Therapy Directed Against B-cell Maturation Antigen (BCMA) in Participants With Multiple Myeloma): Overall Status ACTIVE_NOT_RECRUITING; Phase PHASE2; Primary Completion 2027-02-26 (ESTIMATED); Lead Sponsor Janssen Research & Development, LLC." ([ClinicalTrials.gov](https://clinicaltrials.gov/study/NCT04133636)) |
| June 2027 | [Venclexta (venetoclax) primary completion](https://sec-api.dev/pdufa/venetoclax) | ABBV | Multiple Myeloma | scheduled | "NCT02899052 (Study of Venetoclax in Combination With Carfilzomib and Dexamethasone in Participants With Relapsed or Refractory Multiple Myeloma (MM)): Overall Status ACTIVE_NOT_RECRUITING; Phase PHASE2; Primary Completion 2027-06 (ESTIMATED); Lead Sponsor AbbVie." ([ClinicalTrials.gov](https://clinicaltrials.gov/study/NCT02899052)) |
| Jun to Sep 2027 | [Venclexta (venetoclax) topline data readout](https://sec-api.dev/pdufa/venetoclax) | ABBV | Multiple Myeloma | scheduled | "NCT02899052 (Study of Venetoclax in Combination With Carfilzomib and Dexamethasone in Participants With Relapsed or Refractory Multiple Myeloma (MM)): Overall Status ACTIVE_NOT_RECRUITING; Phase PHASE2; Primary Completion 2027-06 (ESTIMATED); Lead Sponsor AbbVie." ([ClinicalTrials.gov](https://clinicaltrials.gov/study/NCT02899052)) |
| Jun to Sep 2027 | [JNJ-79635322 topline data readout](https://sec-api.dev/pdufa/jnj-79635322) | JNJ | Multiple Myeloma | scheduled | "NCT07266441 (A Study of JNJ-79635322 in Participants With Relapsed or Refractory Multiple Myeloma): Overall Status ACTIVE_NOT_RECRUITING; Phase PHASE2; Primary Completion 2027-06-14 (ESTIMATED); Lead Sponsor Janssen Research & Development, LLC." ([ClinicalTrials.gov](https://clinicaltrials.gov/study/NCT07266441)) |
| June 2027 | [JNJ-79635322 primary completion](https://sec-api.dev/pdufa/jnj-79635322) | JNJ | Multiple Myeloma | scheduled | "NCT07266441 (A Study of JNJ-79635322 in Participants With Relapsed or Refractory Multiple Myeloma): Overall Status ACTIVE_NOT_RECRUITING; Phase PHASE2; Primary Completion 2027-06-14 (ESTIMATED); Lead Sponsor Janssen Research & Development, LLC." ([ClinicalTrials.gov](https://clinicaltrials.gov/study/NCT07266441)) |
| Jul to Oct 2027 | [DARZALEX (daratumumab) topline data readout](https://sec-api.dev/pdufa/daratumumab) | JNJ | Multiple Myeloma | scheduled | "NCT05455320 (A Study Comparing Talquetamab in Combination With Daratumumab or in Combination With Daratumumab and Pomalidomide Versus Daratumumab in Combination With Pomalidomide and Dexamethasone in Participants With Multiple Myeloma That Returns After Treatment or is Resistant to Treatment): Overall Status ACTIVE_NOT_RECRUITING; Phase PHASE3; Primary Completion 2027-07-30 (ESTIMATED); Lead Sponsor Janssen Research & Development, LLC." ([ClinicalTrials.gov](https://clinicaltrials.gov/study/NCT05455320)) |
| July 2027 | [DARZALEX (daratumumab) primary completion](https://sec-api.dev/pdufa/daratumumab) | JNJ | Multiple Myeloma | scheduled | "NCT05455320 (A Study Comparing Talquetamab in Combination With Daratumumab or in Combination With Daratumumab and Pomalidomide Versus Daratumumab in Combination With Pomalidomide and Dexamethasone in Participants With Multiple Myeloma That Returns After Treatment or is Resistant to Treatment): Overall Status ACTIVE_NOT_RECRUITING; Phase PHASE3; Primary Completion 2027-07-30 (ESTIMATED); Lead Sponsor Janssen Research & Development, LLC." ([ClinicalTrials.gov](https://clinicaltrials.gov/study/NCT05455320)) |
| Aug to Nov 2027 | [Elrexfio (elranatamab) topline data readout](https://sec-api.dev/pdufa/elranatamab) | PFE | Multiple Myeloma | scheduled | "NCT05317416 (Study With Elranatamab Versus Lenalidomide in Patients With Newly Diagnosed Multiple Myeloma After Transplant): Overall Status ACTIVE_NOT_RECRUITING; Phase PHASE3; Primary Completion 2027-08-04 (ESTIMATED); Lead Sponsor Pfizer." ([ClinicalTrials.gov](https://clinicaltrials.gov/study/NCT05317416)) |
| Aug to Nov 2027 | [Cilta-cel topline data readout](https://sec-api.dev/pdufa/cilta-cel) | JNJ | Multiple Myeloma | scheduled | "NCT06550895 (A Study of Ciltacabtagene Autoleucel and Talquetamab for the Treatment of Participants With High-Risk Multiple Myeloma): Overall Status ACTIVE_NOT_RECRUITING; Phase PHASE2; Primary Completion 2027-08-26 (ESTIMATED); Lead Sponsor Janssen Research & Development, LLC." ([ClinicalTrials.gov](https://clinicaltrials.gov/study/NCT06550895)) |
| August 2027 | [Elrexfio (elranatamab) primary completion](https://sec-api.dev/pdufa/elranatamab) | PFE | Multiple Myeloma | scheduled | "NCT05317416 (Study With Elranatamab Versus Lenalidomide in Patients With Newly Diagnosed Multiple Myeloma After Transplant): Overall Status ACTIVE_NOT_RECRUITING; Phase PHASE3; Primary Completion 2027-08-04 (ESTIMATED); Lead Sponsor Pfizer." ([ClinicalTrials.gov](https://clinicaltrials.gov/study/NCT05317416)) |
| August 2027 | [Cilta-cel primary completion](https://sec-api.dev/pdufa/cilta-cel) | JNJ | Multiple Myeloma | scheduled | "NCT06550895 (A Study of Ciltacabtagene Autoleucel and Talquetamab for the Treatment of Participants With High-Risk Multiple Myeloma): Overall Status ACTIVE_NOT_RECRUITING; Phase PHASE2; Primary Completion 2027-08-26 (ESTIMATED); Lead Sponsor Janssen Research & Development, LLC." ([ClinicalTrials.gov](https://clinicaltrials.gov/study/NCT06550895)) |
| Nov 2027 to Feb 2028 | [Zenbexus (iberdomide hydrochloride) topline data readout](https://sec-api.dev/pdufa/iberdomide) | BMY | Multiple Myeloma | scheduled | "NCT04975997 (Open-label Study Comparing Iberdomide, Daratumumab and Dexamethasone (IberDd) Versus Daratumumab, Bortezomib, and Dexamethasone (DVd) in Participants With Relapsed or Refractory Multiple Myeloma (RRMM)): Overall Status ACTIVE_NOT_RECRUITING; Phase PHASE3; Primary Completion 2027-11-16 (ESTIMATED); Lead Sponsor Celgene." ([ClinicalTrials.gov](https://clinicaltrials.gov/study/NCT04975997)) |
| November 2027 | [Zenbexus (iberdomide hydrochloride) primary completion](https://sec-api.dev/pdufa/iberdomide) | BMY | Multiple Myeloma | scheduled | "NCT04975997 (Open-label Study Comparing Iberdomide, Daratumumab and Dexamethasone (IberDd) Versus Daratumumab, Bortezomib, and Dexamethasone (DVd) in Participants With Relapsed or Refractory Multiple Myeloma (RRMM)): Overall Status ACTIVE_NOT_RECRUITING; Phase PHASE3; Primary Completion 2027-11-16 (ESTIMATED); Lead Sponsor Celgene." ([ClinicalTrials.gov](https://clinicaltrials.gov/study/NCT04975997)) |
| December 2027 | [Etentamig primary completion](https://sec-api.dev/pdufa/etentamig) | ABBV | Multiple Myeloma | scheduled | "NCT06158841 (Study Assessing Activity of Intravenous (IV) Etentamig Monotherapy Versus Standard Available Therapies in Adult Participants With Relapsed or Refractory Multiple Myeloma): Overall Status ACTIVE_NOT_RECRUITING; Phase PHASE3; Primary Completion 2027-12 (ESTIMATED); Lead Sponsor AbbVie." ([ClinicalTrials.gov](https://clinicaltrials.gov/study/NCT06158841)) |
| Dec 2027 to Mar 2028 | [Etentamig topline data readout](https://sec-api.dev/pdufa/etentamig) | ABBV | Multiple Myeloma | scheduled | "NCT06158841 (Study Assessing Activity of Intravenous (IV) Etentamig Monotherapy Versus Standard Available Therapies in Adult Participants With Relapsed or Refractory Multiple Myeloma): Overall Status ACTIVE_NOT_RECRUITING; Phase PHASE3; Primary Completion 2027-12 (ESTIMATED); Lead Sponsor AbbVie." ([ClinicalTrials.gov](https://clinicaltrials.gov/study/NCT06158841)) |
| Dec 2027 to Mar 2028 | [Ramantamig topline data readout](https://sec-api.dev/pdufa/ramantamig) | JNJ | Multiple Myeloma | scheduled | "NCT07589634 (A Study Evaluating the Prophylactic Use of Tocilizumab to Prevent Cytokine Release Syndrome With Ramantamig Administration in Participants With Relapsed/Refractory Multiple Myeloma): Overall Status RECRUITING; Phase PHASE2; Primary Completion 2027-12-31 (ESTIMATED); Lead Sponsor Janssen Research & Development, LLC." ([ClinicalTrials.gov](https://clinicaltrials.gov/study/NCT07589634)) |
| December 2027 | [Ramantamig primary completion](https://sec-api.dev/pdufa/ramantamig) | JNJ | Multiple Myeloma | scheduled | "NCT07589634 (A Study Evaluating the Prophylactic Use of Tocilizumab to Prevent Cytokine Release Syndrome With Ramantamig Administration in Participants With Relapsed/Refractory Multiple Myeloma): Overall Status RECRUITING; Phase PHASE2; Primary Completion 2027-12-31 (ESTIMATED); Lead Sponsor Janssen Research & Development, LLC." ([ClinicalTrials.gov](https://clinicaltrials.gov/study/NCT07589634)) |
| Apr to Jul 2028 | [Cilta-cel topline data readout](https://sec-api.dev/pdufa/cilta-cel) | JNJ | Multiple Myeloma | scheduled | "NCT07149857 (A Study to Evaluate Efficacy and Safety of Ciltacabtagene Autoleucel): Overall Status RECRUITING; Phase PHASE2; Primary Completion 2028-04-12 (ESTIMATED); Lead Sponsor Janssen Research & Development, LLC." ([ClinicalTrials.gov](https://clinicaltrials.gov/study/NCT07149857)) |
| April 2028 | [Cilta-cel primary completion](https://sec-api.dev/pdufa/cilta-cel) | JNJ | Multiple Myeloma | scheduled | "NCT07149857 (A Study to Evaluate Efficacy and Safety of Ciltacabtagene Autoleucel): Overall Status RECRUITING; Phase PHASE2; Primary Completion 2028-04-12 (ESTIMATED); Lead Sponsor Janssen Research & Development, LLC." ([ClinicalTrials.gov](https://clinicaltrials.gov/study/NCT07149857)) |
| July 2028 | [Anitocabtagene autoleucel primary completion](https://sec-api.dev/pdufa/anitocabtagene-autoleucel) | GILD | Multiple Myeloma | scheduled | "NCT06413498 (A Study Comparing Anitocabtagene Autoleucel to Standard of Care Therapy in Participants With Relapsed/ Refractory Multiple Myeloma): Overall Status ACTIVE_NOT_RECRUITING; Phase PHASE3; Primary Completion 2028-07 (ESTIMATED); Lead Sponsor Kite, A Gilead Company." ([ClinicalTrials.gov](https://clinicaltrials.gov/study/NCT06413498)) |
| Jul to Oct 2028 | [Anitocabtagene autoleucel topline data readout](https://sec-api.dev/pdufa/anitocabtagene-autoleucel) | GILD | Multiple Myeloma | scheduled | "NCT06413498 (A Study Comparing Anitocabtagene Autoleucel to Standard of Care Therapy in Participants With Relapsed/ Refractory Multiple Myeloma): Overall Status ACTIVE_NOT_RECRUITING; Phase PHASE3; Primary Completion 2028-07 (ESTIMATED); Lead Sponsor Kite, A Gilead Company." ([ClinicalTrials.gov](https://clinicaltrials.gov/study/NCT06413498)) |
| Dec 2028 to Mar 2029 | [JNJ-79635322 topline data readout](https://sec-api.dev/pdufa/jnj-79635322) | JNJ | Multiple Myeloma | scheduled | "NCT07258511 (A Study Comparing JNJ-79635322 and an Anti-B-cell Maturation Antigen (BCMA)xCD3 Bispecific Antibody in Participants With Relapsed or Refractory Multiple Myeloma): Overall Status RECRUITING; Phase PHASE3; Primary Completion 2028-12-12 (ESTIMATED); Lead Sponsor Janssen Research & Development, LLC." ([ClinicalTrials.gov](https://clinicaltrials.gov/study/NCT07258511)) |
| December 2028 | [JNJ-79635322 primary completion](https://sec-api.dev/pdufa/jnj-79635322) | JNJ | Multiple Myeloma | scheduled | "NCT07258511 (A Study Comparing JNJ-79635322 and an Anti-B-cell Maturation Antigen (BCMA)xCD3 Bispecific Antibody in Participants With Relapsed or Refractory Multiple Myeloma): Overall Status RECRUITING; Phase PHASE3; Primary Completion 2028-12-12 (ESTIMATED); Lead Sponsor Janssen Research & Development, LLC." ([ClinicalTrials.gov](https://clinicaltrials.gov/study/NCT07258511)) |
| Jan to Apr 2029 | [DARZALEX (daratumumab) topline data readout](https://sec-api.dev/pdufa/daratumumab) | JNJ | Multiple Myeloma | scheduled | "NCT05438043 (A Study of Daratumumab): Overall Status ACTIVE_NOT_RECRUITING; Phase PHASE3; Primary Completion 2029-01-31 (ESTIMATED); Lead Sponsor Janssen Research & Development, LLC." ([ClinicalTrials.gov](https://clinicaltrials.gov/study/NCT05438043)) |
| January 2029 | [DARZALEX (daratumumab) primary completion](https://sec-api.dev/pdufa/daratumumab) | JNJ | Multiple Myeloma | scheduled | "NCT05438043 (A Study of Daratumumab): Overall Status ACTIVE_NOT_RECRUITING; Phase PHASE3; Primary Completion 2029-01-31 (ESTIMATED); Lead Sponsor Janssen Research & Development, LLC." ([ClinicalTrials.gov](https://clinicaltrials.gov/study/NCT05438043)) |
| Feb to May 2029 | [Revlimid® (lenalidomide) topline data readout](https://sec-api.dev/pdufa/lenalidomide) | JNJ | Multiple Myeloma | scheduled | "NCT04923893 (A Study of Bortezomib, Lenalidomide and Dexamethasone (VRd) Followed by Cilta-cel, a CAR-T Therapy Directed Against BCMA Versus VRd Followed by Lenalidomide and Dexamethasone (Rd) Therapy in Participants With Newly Diagnosed Multiple Myeloma for Whom ASCT is Not Planned as Initial Therapy): Overall Status ACTIVE_NOT_RECRUITING; Phase PHASE3; Primary Completion 2029-02-14 (ESTIMATED); Lead Sponsor Janssen Research & Development, LLC." ([ClinicalTrials.gov](https://clinicaltrials.gov/study/NCT04923893)) |
| Feb to May 2029 | [Belantamab mafodotin topline data readout](https://sec-api.dev/pdufa/belantamab-mafodotin) | GSK | Multiple Myeloma | scheduled | "NCT07614360 (Study of Alternative and Approved Dosing Regimens of Belantamab Mafodotin, Bortezomib, and Dexamethasone (BVd) in Participants With Relapsed/Refractory Multiple Myeloma): Overall Status NOT_YET_RECRUITING; Phase PHASE2; Primary Completion 2029-02-28 (ESTIMATED); Lead Sponsor GlaxoSmithKline." ([ClinicalTrials.gov](https://clinicaltrials.gov/study/NCT07614360)) |
| February 2029 | [Revlimid® (lenalidomide) primary completion](https://sec-api.dev/pdufa/lenalidomide) | JNJ | Multiple Myeloma | scheduled | "NCT04923893 (A Study of Bortezomib, Lenalidomide and Dexamethasone (VRd) Followed by Cilta-cel, a CAR-T Therapy Directed Against BCMA Versus VRd Followed by Lenalidomide and Dexamethasone (Rd) Therapy in Participants With Newly Diagnosed Multiple Myeloma for Whom ASCT is Not Planned as Initial Therapy): Overall Status ACTIVE_NOT_RECRUITING; Phase PHASE3; Primary Completion 2029-02-14 (ESTIMATED); Lead Sponsor Janssen Research & Development, LLC." ([ClinicalTrials.gov](https://clinicaltrials.gov/study/NCT04923893)) |
| February 2029 | [Belantamab mafodotin primary completion](https://sec-api.dev/pdufa/belantamab-mafodotin) | GSK | Multiple Myeloma | scheduled | "NCT07614360 (Study of Alternative and Approved Dosing Regimens of Belantamab Mafodotin, Bortezomib, and Dexamethasone (BVd) in Participants With Relapsed/Refractory Multiple Myeloma): Overall Status NOT_YET_RECRUITING; Phase PHASE2; Primary Completion 2029-02-28 (ESTIMATED); Lead Sponsor GlaxoSmithKline." ([ClinicalTrials.gov](https://clinicaltrials.gov/study/NCT07614360)) |
| Mar to Jun 2029 | [Zenbexus (iberdomide hydrochloride) topline data readout](https://sec-api.dev/pdufa/iberdomide) | BMY | Multiple Myeloma | scheduled | "NCT05827016 (A Study to Compare Iberdomide Maintenance Versus Lenalidomide Maintenance Therapy Following Autologous Stem Cell Transplant in Participants With Newly Diagnosed Multiple Myeloma): Overall Status ACTIVE_NOT_RECRUITING; Phase PHASE3; Primary Completion 2029-03-15 (ESTIMATED); Lead Sponsor Bristol-Myers Squibb." ([ClinicalTrials.gov](https://clinicaltrials.gov/study/NCT05827016)) |
| March 2029 | [Zenbexus (iberdomide hydrochloride) primary completion](https://sec-api.dev/pdufa/iberdomide) | BMY | Multiple Myeloma | scheduled | "NCT05827016 (A Study to Compare Iberdomide Maintenance Versus Lenalidomide Maintenance Therapy Following Autologous Stem Cell Transplant in Participants With Newly Diagnosed Multiple Myeloma): Overall Status ACTIVE_NOT_RECRUITING; Phase PHASE3; Primary Completion 2029-03-15 (ESTIMATED); Lead Sponsor Bristol-Myers Squibb." ([ClinicalTrials.gov](https://clinicaltrials.gov/study/NCT05827016)) |
| Apr to Jul 2029 | [JNJ-79635322 topline data readout](https://sec-api.dev/pdufa/jnj-79635322) | JNJ | Multiple Myeloma | scheduled | "NCT07518186 (A Study Comparing JNJ-79635322 and Teclistamab in Participants With Relapsed or Refractory Multiple Myeloma): Overall Status RECRUITING; Phase PHASE3; Primary Completion 2029-04-29 (ESTIMATED); Lead Sponsor Janssen Research & Development, LLC." ([ClinicalTrials.gov](https://clinicaltrials.gov/study/NCT07518186)) |
| April 2029 | [JNJ-79635322 primary completion](https://sec-api.dev/pdufa/jnj-79635322) | JNJ | Multiple Myeloma | scheduled | "NCT07518186 (A Study Comparing JNJ-79635322 and Teclistamab in Participants With Relapsed or Refractory Multiple Myeloma): Overall Status RECRUITING; Phase PHASE3; Primary Completion 2029-04-29 (ESTIMATED); Lead Sponsor Janssen Research & Development, LLC." ([ClinicalTrials.gov](https://clinicaltrials.gov/study/NCT07518186)) |
| May to Aug 2030 | [Talquetamab topline data readout](https://sec-api.dev/pdufa/talquetamab) | JNJ | Multiple Myeloma | scheduled | "NCT06500884 (A Study to Evaluate Preventive Treatments for GPRC5D-related Oral Events): Overall Status RECRUITING; Phase PHASE2; Primary Completion 2030-05-30 (ESTIMATED); Lead Sponsor Janssen Research & Development, LLC." ([ClinicalTrials.gov](https://clinicaltrials.gov/study/NCT06500884)) |
| May 2030 | [Talquetamab primary completion](https://sec-api.dev/pdufa/talquetamab) | JNJ | Multiple Myeloma | scheduled | "NCT06500884 (A Study to Evaluate Preventive Treatments for GPRC5D-related Oral Events): Overall Status RECRUITING; Phase PHASE2; Primary Completion 2030-05-30 (ESTIMATED); Lead Sponsor Janssen Research & Development, LLC." ([ClinicalTrials.gov](https://clinicaltrials.gov/study/NCT06500884)) |
| Aug to Nov 2030 | [Belantamab mafodotin topline data readout](https://sec-api.dev/pdufa/belantamab-mafodotin) | GSK | Multiple Myeloma | scheduled | "NCT07227311 (A Study to Evaluate the Efficacy and Safety of Belantamab Mafodotin in Combination With Standard of Care in Participants With Relapsed-Refractory Multiple Myeloma (RRMM)): Overall Status RECRUITING; Phase PHASE2; Primary Completion 2030-08-30 (ESTIMATED); Lead Sponsor GlaxoSmithKline." ([ClinicalTrials.gov](https://clinicaltrials.gov/study/NCT07227311)) |
| August 2030 | [Belantamab mafodotin primary completion](https://sec-api.dev/pdufa/belantamab-mafodotin) | GSK | Multiple Myeloma | scheduled | "NCT07227311 (A Study to Evaluate the Efficacy and Safety of Belantamab Mafodotin in Combination With Standard of Care in Participants With Relapsed-Refractory Multiple Myeloma (RRMM)): Overall Status RECRUITING; Phase PHASE2; Primary Completion 2030-08-30 (ESTIMATED); Lead Sponsor GlaxoSmithKline." ([ClinicalTrials.gov](https://clinicaltrials.gov/study/NCT07227311)) |
| Sep to Dec 2030 | [DARZALEX (daratumumab) topline data readout](https://sec-api.dev/pdufa/daratumumab) | JNJ | Multiple Myeloma | scheduled | "NCT06577025 (A Study of Different Sequences of Cilta-cel, Talquetamab in Combination With Daratumumab and Teclistamab in Combination With Daratumumab Following Induction With Daratumumab, Bortezomib, Lenalidomide and Dexamethasone in Participants With Standard-risk Newly Diagnosed Multiple Myeloma): Overall Status ACTIVE_NOT_RECRUITING; Phase PHASE2; Primary Completion 2030-09-02 (ESTIMATED); Lead Sponsor Janssen Research & Development, LLC." ([ClinicalTrials.gov](https://clinicaltrials.gov/study/NCT06577025)) |
| Sep to Dec 2030 | [DARZALEX (daratumumab) topline data readout](https://sec-api.dev/pdufa/daratumumab) | JNJ | Multiple Myeloma | scheduled | "NCT07665450 (A Study of Ramantamig Plus Daratumumab Versus Daratumumab, Bortezomib, Lenalidomide, and Dexamethasone (DVRd) or Daratumumab, Lenalidomide, and Dexamethasone (DRd) in Participants With NDMM For Whom Stem Cell Transplant is Not Planned): Overall Status RECRUITING; Phase PHASE3; Primary Completion 2030-09-04 (ESTIMATED); Lead Sponsor Janssen Research & Development, LLC." ([ClinicalTrials.gov](https://clinicaltrials.gov/study/NCT07665450)) |
| September 2030 | [DARZALEX (daratumumab) primary completion](https://sec-api.dev/pdufa/daratumumab) | JNJ | Multiple Myeloma | scheduled | "NCT06577025 (A Study of Different Sequences of Cilta-cel, Talquetamab in Combination With Daratumumab and Teclistamab in Combination With Daratumumab Following Induction With Daratumumab, Bortezomib, Lenalidomide and Dexamethasone in Participants With Standard-risk Newly Diagnosed Multiple Myeloma): Overall Status ACTIVE_NOT_RECRUITING; Phase PHASE2; Primary Completion 2030-09-02 (ESTIMATED); Lead Sponsor Janssen Research & Development, LLC." ([ClinicalTrials.gov](https://clinicaltrials.gov/study/NCT06577025)) |
| September 2030 | [DARZALEX (daratumumab) primary completion](https://sec-api.dev/pdufa/daratumumab) | JNJ | Multiple Myeloma | scheduled | "NCT07665450 (A Study of Ramantamig Plus Daratumumab Versus Daratumumab, Bortezomib, Lenalidomide, and Dexamethasone (DVRd) or Daratumumab, Lenalidomide, and Dexamethasone (DRd) in Participants With NDMM For Whom Stem Cell Transplant is Not Planned): Overall Status RECRUITING; Phase PHASE3; Primary Completion 2030-09-04 (ESTIMATED); Lead Sponsor Janssen Research & Development, LLC." ([ClinicalTrials.gov](https://clinicaltrials.gov/study/NCT07665450)) |
| Oct 2030 to Jan 2031 | [Elrexfio (elranatamab) topline data readout](https://sec-api.dev/pdufa/elranatamab) | PFE | Multiple Myeloma | scheduled | "NCT05623020 (A Study to Learn About the Effects of the Combination of Elranatamab, Daratumumab and Lenalidomide Compared With Daratumumab, Bortezomib, Lenalidomide, and Dexamethasone in Patients With Newly Diagnosed Multiple Myeloma Who Are Not Candidates for Transplant): Overall Status RECRUITING; Phase PHASE3; Primary Completion 2030-10-18 (ESTIMATED); Lead Sponsor Pfizer." ([ClinicalTrials.gov](https://clinicaltrials.gov/study/NCT05623020)) |
| October 2030 | [Elrexfio (elranatamab) primary completion](https://sec-api.dev/pdufa/elranatamab) | PFE | Multiple Myeloma | scheduled | "NCT05623020 (A Study to Learn About the Effects of the Combination of Elranatamab, Daratumumab and Lenalidomide Compared With Daratumumab, Bortezomib, Lenalidomide, and Dexamethasone in Patients With Newly Diagnosed Multiple Myeloma Who Are Not Candidates for Transplant): Overall Status RECRUITING; Phase PHASE3; Primary Completion 2030-10-18 (ESTIMATED); Lead Sponsor Pfizer." ([ClinicalTrials.gov](https://clinicaltrials.gov/study/NCT05623020)) |

## Drugs

- [APHEXDA® (motixafortide)](https://sec-api.dev/pdufa/motixafortide) (BLRX)
- [PHE885](https://sec-api.dev/pdufa/phe885) (NVS)
- [DARZALEX (daratumumab)](https://sec-api.dev/pdufa/daratumumab) (JNJ)
- [ABECMA (idecabtagene vicleucel)](https://sec-api.dev/pdufa/idecabtagene-vicleucel) (BMY)
- [TECVAYLI (teclistamab)](https://sec-api.dev/pdufa/teclistamab) (JNJ)
- [BB2121](https://sec-api.dev/pdufa/bb2121) (BMY)
- [Empliciti (elotuzumab)](https://sec-api.dev/pdufa/elotuzumab) (BMY)
- [Elrexfio (elranatamab)](https://sec-api.dev/pdufa/elranatamab) (PFE)
- [Talquetamab](https://sec-api.dev/pdufa/talquetamab) (JNJ)
- [Pomalyst (pomalidomide)](https://sec-api.dev/pdufa/pomalidomide) (BMY)
- [Arlocabtagene autoleucel](https://sec-api.dev/pdufa/arlocabtagene-autoleucel) (BMY)
- [Venclexta (venetoclax)](https://sec-api.dev/pdufa/venetoclax) (ABBV)
- [Anitocabtagene autoleucel](https://sec-api.dev/pdufa/anitocabtagene-autoleucel) (GILD)
- [JNJ-79635322](https://sec-api.dev/pdufa/jnj-79635322) (JNJ)
- [Cilta-cel](https://sec-api.dev/pdufa/cilta-cel) (JNJ)
- [Zenbexus (iberdomide hydrochloride)](https://sec-api.dev/pdufa/iberdomide) (BMY)
- [Etentamig](https://sec-api.dev/pdufa/etentamig) (ABBV)
- [Ramantamig](https://sec-api.dev/pdufa/ramantamig) (JNJ)
- [Revlimid® (lenalidomide)](https://sec-api.dev/pdufa/lenalidomide) (JNJ)
- [Belantamab mafodotin](https://sec-api.dev/pdufa/belantamab-mafodotin) (GSK)

## Feeds and downloads

- Subscribe (iCal): https://sec-api.dev/indications/multiple-myeloma.ics
- Next 30 days as CSV: https://sec-api.dev/fda-calendar.csv . JSON: https://sec-api.dev/fda-calendar.json . All events (iCal): https://sec-api.dev/fda-calendar.ics
- New or moved PDUFA dates: https://sec-api.dev/pdufa-dates/feed.xml (RSS), https://sec-api.dev/pdufa-dates/feed.json (JSON Feed)
- FDA approvals: https://sec-api.dev/fda-approvals-today/feed.xml (RSS), https://sec-api.dev/fda-approvals-today/feed.json (JSON Feed)
- License: CC BY 4.0 for the public 30-day window (https://sec-api.dev/biotech/license.txt). Full history: https://sec-api.dev/pricing

## Cite this page

sec-api.dev. "multiple myeloma FDA approvals and PDUFA dates." Biotech catalyst calendar, data as of November 16, 2026 (snapshot 20261116T222116Z). https://sec-api.dev/indications/multiple-myeloma

```bibtex
@misc{secapidev_indications_multiple_myeloma_20261116,
  title        = {multiple myeloma FDA approvals and PDUFA dates},
  author       = {{sec-api.dev}},
  year         = {2026},
  month        = {nov},
  howpublished = {\url{https://sec-api.dev/indications/multiple-myeloma}},
  note         = {Biotech catalyst calendar, data as of 2026-11-16, snapshot 20261116T222116Z. Compiled from SEC EDGAR filings, FDA and ClinicalTrials.gov; each date quotes its source.}
}
```

```json
{"type":"dataset","id":"secapidev_indications_multiple_myeloma_20261116","title":"multiple myeloma FDA approvals and PDUFA dates","publisher":"sec-api.dev","URL":"https://sec-api.dev/indications/multiple-myeloma","issued":{"date-parts":[[2026,11,16]]},"version":"20261116T222116Z","license":"https://creativecommons.org/licenses/by/4.0/","note":"Compiled from SEC EDGAR filings, FDA and ClinicalTrials.gov; each date quotes its source."}
```

---
Independent. Not affiliated with, endorsed by, or sponsored by the U.S. Food and Drug Administration or the U.S. Securities and Exchange Commission. Dates are as stated by sponsors and FDA; the FDA can act before or after a target date. Not investment advice.
